Vaxcyte (PCVX) Gains from Sales and Divestitures (2022 - 2023)
Vaxcyte (PCVX) reported Gains from Sales and Divestitures of $232890.0 for Q4 2023, up 193.95% year-over-year from $79229.0 in Q4 2022, and up 7.5% quarter-over-quarter from $216636.0 in Q3 2023.
Vaxcyte (PCVX) Gains from Sales and Divestitures (2022 - 2023) Analysis & Trends
Vaxcyte (PCVX) has 2 years of Gains from Sales and Divestitures data on file, last reported at $232890.0 in Q4 2023.
- Gains from Sales and Divestitures for Q4 2023 came in at $232890.0, up 193.95% year-over-year; the trailing twelve-month figure through Dec 2023 was $232890.0 (up 193.95% YoY), and the FY2023 annual result was $232890.0, up 193.95% from the prior year.
- Gains from Sales and Divestitures advanced to $232890.0 in Q4 2023 per PCVX's latest filing, from $216636.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $232890.0 in Q4 2023 and troughed at $45206.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Vaxcyte | 6.34 Bn | 6.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 232,890.00 |
| Dec 31, 2023 | 232,890.00 |
| Sep 30, 2023 | 216,636.00 |
| Sep 30, 2023 | 216,636.00 |
| Jun 30, 2023 | 78,055.00 |
| Jun 30, 2023 | 78,055.00 |
| Mar 31, 2023 | 45,206.00 |
| Mar 31, 2023 | 45,206.00 |
| Dec 31, 2022 | 79,229.00 |
| Dec 31, 2022 | 79,229.00 |
| Sep 30, 2022 | 79,229.00 |
| Sep 30, 2022 | 79,229.00 |